Pipeline
Our pipeline demonstrates the ability of our AI-driven drug discovery platform to create precision engineered, patient-centric therapeutic candidates.
Programme
Target
Late Discovery
IND-enabling
Phase 1/2
Pivotal / Approved
Exscientia Rights
PKC-theta is in a Phase 1 healthy volunteer (HV) study; AML = acute myeloid leukaemia; SCLC = small-cell lung cancer